Axiom Investors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Axiom Investors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-114,180	Closed	-$637K	–	148
2015 Q4	$637K	Buy	114,180 +59,610	+109%	+$394K	0.02%	128
2015 Q3	$462K	Buy	+54,570	New	+$923K	0.01%	125

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Axiom Investors's PETX Position: Q1 2016 in Review

Axiom Investors sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2016, closing a stake of 114,180 shares — an estimated $637K sold.

Axiom Investors first reported a position in PETX in Q3 2015 and held it in 2 quarters. The position peaked at $637K in Q4 2015. 95 funds tracked by Wall St. Rank hold PETX as of Q1 2016.

Axiom Investors reported no remaining Aratana Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Axiom Investors sold 114,180 Aratana Therapeutics, Inc. shares in Q1 2016, an estimated $637K.
Axiom Investors first reported a position in Aratana Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
Axiom Investors's Aratana Therapeutics, Inc. position peaked at $637K in Q4 2015.
95 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2016.

Based on Axiom Investors's 13F filing for Q1 2016, filed 12 May 2016.